0001193805-23-001002.txt : 20230718 0001193805-23-001002.hdr.sgml : 20230718 20230718185025 ACCESSION NUMBER: 0001193805-23-001002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kummerfeld Keith C CENTRAL INDEX KEY: 0001762749 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38942 FILM NUMBER: 231095276 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcturus Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001768224 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8589002660 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 e618788_4-kummerfeld.xml X0508 4 2023-07-14 0 0001768224 Arcturus Therapeutics Holdings Inc. ARCT 0001762749 Kummerfeld Keith C C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10628 SCIENCE CENTER DRIVE, SUITE 250 SAN DIEGO CA 92121 0 1 0 0 See Remarks 0 Common Stock 2023-07-14 4 M 0 4500 9.04 A 5450 D Common Stock 2023-07-14 4 M 0 1437 4.99 A 6887 D Common Stock 2023-07-14 4 M 0 1031 14.12 A 7918 D Common Stock 2023-07-14 4 S 0 6968 35.00 D 950 D Employee Stock Option (right to buy) 9.04 2023-07-14 4 M 0 4500 0.00 D 2028-07-04 Common Stock 4500 21000 D Employee Stock Option (right to buy) 4.99 2023-07-14 4 M 0 1437 0.00 D 2029-02-06 Common Stock 1437 7126 D Employee Stock Option (right to buy) 14.12 2023-07-14 4 M 0 1031 0.00 D 2030-02-18 Common Stock 1031 7938 D Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023. 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Senior Vice President of Finance (Principal Accounting Officer) /s/ Ilan Katz, attorney-in-fact 2023-07-18